Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Prospective, randomized, double-masked, placebo-controlled clinical study to define the
effective use of a topical non-steroidal anti-inflammatory drug added to topical steroid use
after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular
edema.